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Cultured human MSCs secretome contains anti inÀ ammatory cy-
tokines and reduces in vitro ischemia reperfusion lesions and T lym-
phocyte proliferation after allogeneic stimulation
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Mesenchymal stem cells (MSCs) may reduce ischemia reperfusion injury 
by paracrine activation of cardioprotective pathways. MSCs may also modu-
late allogeneic rejection by secretion of cytokines. We hypothesised that 
human MSCs secretome may contain an anti inÀ ammatory cocktail of cyto-
kines that could reduce both ischemia reperfusion injuries and allogeneic 
rejection at the time of organ transplantation.
Methods and results: Serum free conditioned media (secretome) was har-
vested after 24, 48, and 72 hours from cultured human MSCs. The best 
results were obtained with secretome harvested after 48 hours of culture. 
Addition of human MSCs secretome at the time of reperfusion in an in 
vitro model of ischemia reperfusion of neonatal rat’s cardiomyocytes signi¿ -
cantly reduced (- 23%±5%) cell death assessed by MTT staining. Addition of 
human MSCs secretome on mixed lymphocytes reaction signi¿ cantly reduced 
(- 22%±3%) T lymphocytes proliferation assessed by the amount of radioac-
tivity measured in a scintillation counter after 3H thymidine incorporation. 
Multiplex analysis of human MSCs secretome (IL- 1, IL- 6, IL- 10, IL- 12, IL- 17, 
TNF- a, VEGF) showed an anti inÀ ammatory pro¿ le of cytokine concentration. 
Conclusion: Our preliminary in vitro data suggest that human MSCs secre-
tome features an anti inÀ ammatory cytokines pro¿ le that may favor the reduc-
tion of ischemia reperfusion injuries and modulate allogeneic rejection.
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Role of thrombospondin - 1 in the remodeling induced by a chronic in-
crease in À ow in resistance arteries
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Backgrounds: Chronic increases in blood À ow induce local inÀ ammation, 
MMP activation, arterial diameter and NO- dependent dilation in resistance arte-
ries. Thrombospondin- 1 (TSP- 1) is a large matricellular glycoprotein secreted by 
many cell types such as endothelial cell, smooth muscle cell and immune cell. 
It is a component of the extracellular matrix during active and subacute pro-
cesses. Due to TSP- 1’s ability to interact with a variety of matrix proteins and 
cell- surface receptors controversy exists about its conÀ icting functions. We inves-
tigated the TSP- 1 effect in a high À ow (HF) mesenteric artery remodeling model.
Material and methods: Arteries were ligated in vivo to generate high- À ow 
arteries compared with normal À ow (control) vessels located at a distance on 
wild type (WT) mice versus TSP- 1deleted mice (TSP- 1 KO). Arteries were 
isolated after 1 week for in vitro analysis. Arteries were thus submitted to high 
À ow (HF), low À ow (LF), or normal À ow. After 2 weeks, arteries were studied 
in vitro in an arteriograph. Arterial reactivity, artery remodeling, and genes 
implicated in the inÀ ammation, were determinated.
Results: Increases in diameter (from 155±6 to 288±10 m, pressure from 15 
to 125mmHg) found in HF WT arteries were not signi¿ cant in TSP- 1 KO arteries 
(from 171±12 to 316±14 m). Dilatory (sodium nitroprusside) and contractile 
(Phenylephrine) tone, depending on the smooth muscle, were unaffected by the 
absence of TSP- 1. Acetylcholine dilation was decreased in TSP- 1 KO arteries.
Four days after ligatures, we demonstrated that CD68, Cox1, Cox2, 
Gp91phox, p47phox, p22phox, VEGFa and TGFb1 expression level were 
signi¿ cantly reduced in the TSP- 1 KO HF arteries compare to wild HF arteries.
Conclusion: The absence of TSP- 1 induces a down regulation of inÀ amma-
tion genes and endothelium dilation de¿ ciency implicated in HF remodeling. 
Blood À ow regulation might be disturbed in TSP- related disease, and could be 
implicated in organ damage.
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Myocardial protection conferred by High Density Lipoproteins impli-
cates Connexin43 gap junction channels
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High Density Lipoprotein (HDL) is known for its cardioprotective proper-
ties independent from its cholesterol transport activity. Connexin43 (Cx43) is a 
gap junction protein present in ventricular cardiomyocytes. We have previously 
showed that 5 minutes of treatment with HDL promoted phosphorylation of Cx43 
by a PKC- dependent mechanism in neonatal rat cardiomyocytes that was asso-
ciated with a signi¿ cant reduction of gap junction permeability between cells but 
no modi¿ cation of electrical coupling. We now investigate how these effects of 
HDL on Cx43 properties are implicated in cardioprotection confered by HDL. To 
this purpose, we performed ex vivo Langendorff perfusion in which HDL is added 
after ischemia during 5 minutes. We showed that HDL signi¿ cantly reduced infarct 
size in response to 30 minutes of no- À ow global ischemia followed by 1 hour 
of reperfusion (Control: 23±3%, HDL: 13±2%, p<0.05). The Left Ventricular 
Developed Pressure was also signi¿ cantly improved by 5min of treatment with 
HDL at the onset of reperfusion (23±6mmHg vs. controls: 8±2mmHg, p<0.05). 
Moreover, 5 minutes of perfusion with HDL at the beginning of the reperfusion 
signi¿ cantly reduced arrhythmias after 15 minutes of regional ischemia (duration 
of ¿ brillation at the reperfusion: Control: 6.4±2min; HDL: 2.3±1min, p<0.05). In 
conclusion, short- term treatment with HDL induces phosphorylation of Cx43 by 
a PKC- dependent pathway that confers cardioprotection against ischemia/reperfu-
sion injury (cell death and arrhythmias). These results link Cx43 for the ¿ rst time 
to the short- term cardioprotective effects of HDL.
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Although mitochondria are key determinants of myocardial injury during 
ischemia- reperfusion (I/R), their interaction with critical cytoprotective signa-
ling systems is not fully understood. Sphingosine- 1- phosphate (S1P) produced by 
sphingosine kinase- 1 protects the heart from I/R damage. Recently a new role for 
mitochondrial S1P produced by a second isoform of sphingosine kinase, SphK2, 
was described to regulate complex IV assembly and respiration via interaction 
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with mitochondrial prohibitin- 2. Here we investigated the role of SphK2 in cardio-
protection by preconditioning. Littermate (WT) and sphk2 (- /- ) mice underwent 
45min of in vivo ischemia and 24 h reperfusion. Mice received no intervention 
(I/R) or preconditioning (PC) via 5min I/R before the index ischemia. Despite 
the activation of PC- cytoprotective signaling pathways in both groups, infarct size 
in sphk2 (- /- ) mice was not reduced by PC (42±3% PC vs. 43±4% I/R, p = ns) 
versus WT (24±3% PC vs. 43±3% I/R, p<0.05). sphk2 (- /- ) mitochondria exhi-
bited decreased oxidative phosphorylation and increased susceptibility to per-
meability transition (PTP). Unlike WT, PC did not prevent ischemic damage to 
electron transport or the increased susceptibility to PTP. To evaluate the direct 
contribution to the resistance of mitochondria to cytoprotection, SphK2, PHB2 or 
cytochrome oxidase subunit IV was depleted in cardiomyoblasts. PC protection 
was abolished by each knockdown concomitant with decreased PTP resistance. 
These results point to a new action of S1P in cardioprotection and suggest that the 
mitochondrial S1P produced by SphK2 is required for the downstream protective 
modulation of PTP as an effector of preconditioning protection.
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Background and aims: Ranolazine (Ranexa) is a novel drug used for 
treatment of patients with chronic stable angina. Ranolazine prevents Na+- 
dependent Ca2+ overload in cardiomyocytes by normalizing the inactivation 
kinetics of a late Na+ current (INaL) promoted in ischemic conditions. Na+ 
channels are present in arteries and INaL was recorded in arterial myocytes. We 
hypothesized that ranolazine also targets arterial contraction. We investigated 
its effect on the contractile function of rat aorta.
Methodology/Principal ¿ ndings: We studied variations in isometric 
tension of aortic rings in response to ranolazine: (i) under basal conditions, 
and, (ii) under pharmacological conditions promoting INaL (by use of vera-
tridine). Ranolazine induced vasodilatation of rat aorta at therapeutic range 
(EC50=3.8±0.3 nM) independently of the endothelium. In a previous work, 
we showed that: (i) moderate depolarization, induced by low KCl, activates 
a Na+ channel- dependent arterial contraction; (ii) this response persists in the 
presence of prazosin, an α1- adrenergic antagonist used to exclude the contri-
bution of Na+ channels from the perivascular sympathetic nerve terminals. 
Here, ranolazine inhibited the Na+ channel- dependent contraction induced by 
low KCl (< 15mM). This inhibition persisted in presence of prazosin, but it 
was blocked by Na+ channel blocker tetrodotoxin (1 M) and similarly by 
the Na+/Ca2+ exchanger inhibitor KB- R7943 (10 M) responsible for Ca2+ 
entry. Ranolazine relaxed 32±3% of contraction induced by 10mM KCl but 
had no effect on contraction induced by 30mM KCl (direct activation of Ca2+ 
channels).
Conclusion: Ranolazine suppresses INaL- dependent arterial contraction. 
This effect may contribute to its anti- anginal properties in addition to the 
reported intracellular effects on cardiomyocytes.
